{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:42:32Z","timestamp":1790685752362,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"S57","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4710,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1996,6]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> The incidence of invasive fungal infections is increasing and new fungal species are emerging as important pathogens. In cancer patients, the main risk factor for the development of systemic fungal disease is severe, prolonged neutropenia. Other factors, such as mucosal damage, presence of a central venous line, immunosuppressive therapy and treatment with broad spectrum antibiotics are contributory. <jats:italic>Candida<\/jats:italic> spp. are the fungi most commonly isolated in neutropenic patients. There has been a dramatic increase in non\u2010<jats:italic>C. albicans<\/jats:italic> species, such as <jats:italic>C. glabrata<\/jats:italic> and <jats:italic>C. krusei<\/jats:italic>, largely as a result of extensive prophylactic and therapeutic use of fluconazole, to which these species are largely resistant. In neutropenic patients with candidaemia, amphotericin B is the drug of choice although the conventional formulation may be poorly tolerated. Lipid\u2010based forms of amphotericin B, such as Abelcet\u00ae, are better tolerated and can be given at a much higher dose and should therefore be considered in patients who fail on or are intolerant to the conventional agent. Aspergillosis is the second most frequent fungal infection in neutropenic patients. Primary invasive aspergillosis usually presents on chest X\u2010ray with lung lesions and the brain is a frequent site of secondary infection. Fluconazole is inactive against <jats:italic>Aspergillus<\/jats:italic> spp. and amphotericin B is the standard treatment. Again, lipid\u2010based forms are better tolerated than the conventional formulation in this setting, and have been shown to achieve response rates of 60% or more in a number of trials. Other potentially life\u2010threatening fungal infections in which lipid\u2010based amphotericin B may play an important therapeutic role in the future include cryptococcosis (increasingly problematic in AIDS patients), trichosporonosis, fusariosis and mucormycosis. Further randomized studies should be performed in a range of fungal infections to compare Abelcet\u00aewith conventional amphotericin B and other lipid\u2010based antifungal agents.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1996.tb01347.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T17:24:35Z","timestamp":1279473875000},"page":"12-17","source":"Crossref","is-referenced-by-count":16,"title":["The changing epidemiology of fungal infections: are the lipid\u2010based forms of amphotericin B an advance?"],"prefix":"10.1111","volume":"56","author":[{"given":"R.","family":"Herbrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1247"},{"key":"e_1_2_1_3_2","volume":"106","author":"Groll A","year":"1994","journal-title":"Changing pattern of invasive mycosis at autopsy"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.Supplement_1.S8"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380120094019"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967060"},{"key":"e_1_2_1_7_2","first-page":"597","article-title":"Candidoses invasives graves. Importance du ph\u00e9nom\u00e8ne et tableaux cliniques","volume":"6","author":"Bleriot JP.","year":"1990","journal-title":"R\u00e9an Soins Intens M\u00e9d Urg"},{"key":"e_1_2_1_8_2","volume":"105","author":"Rangel\u2010Frausto MS","year":"1994","journal-title":"High prevalence of Candida spp. on hands of health care workers in surgical and neonatal intensive care units: a multicenter study"},{"issue":"4","key":"e_1_2_1_9_2","first-page":"20","article-title":"Systemic candidiasis in cancer patients","volume":"77","author":"Maksymiuk AW","year":"1984","journal-title":"Am J Med"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/11.3.379"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110313251803"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91314-9"},{"key":"e_1_2_1_13_2","volume":"9","author":"DuBois D","year":"1994","journal-title":"Emergence of non-Candida albicans fungemia in bone marrow transplant patients receiving fluconazole"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.1989.00390100145030","article-title":"Risk factors for hospital\u2010acquired candidemia: a matched case\u2010control study","volume":"149","author":"Wey SB","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.26.3.429-432.1988"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411173312001"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90023-X"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.6.1147"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.73"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.93"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.5.1145"},{"key":"e_1_2_1_22_2","volume":"247","author":"Walsh TJ","year":"1994","journal-title":"Amphotericin B Lipid Complex in the treatment of 228 cases of invasive mycosis"},{"issue":"1","key":"e_1_2_1_23_2","first-page":"306a","article-title":"Amphotericin B Lipid Complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy","volume":"84","author":"Lister J.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_24_2","volume-title":"Data on file","year":"1993"},{"key":"e_1_2_1_25_2","first-page":"129","article-title":"Trichosporon infections: clinical manifestations and treatment","volume":"3","author":"Herbrecht R","year":"1993","journal-title":"J Mycol Med"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1996.tb01347.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1996.tb01347.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:06:00Z","timestamp":1698332760000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1996.tb01347.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,6]]},"references-count":24,"journal-issue":{"issue":"S57","published-print":{"date-parts":[[1996,6]]}},"alternative-id":["10.1111\/j.1600-0609.1996.tb01347.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1996.tb01347.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,6]]}}}